The Office of the U.S. Trade Representative has extended from Sept. 30 to Nov. 14 the current exclusions from the Section 301 additional tariffs on imports from China for 99 medical care products needed to address the COVID-19 pandemic. USTR indicates that this interim extension will enable it to review the public comments that were submitted through Sept. 27 on whether the exclusions should be extended for up to six months.
The exclusions (click here for full list) are available for any product that meets the specified HTSUS numbers and product descriptions, regardless of whether the importer filed an exclusion request.
USTR states that it will evaluate each exclusion request on a case-by-case basis. This evaluation will examine whether it remains appropriate to exclude the product in light of the spread of the Delta variant of COVID-19 as well as increased domestic production of certain products. USTR will also take into account the overall impact of these exclusions on the goal of obtaining the elimination of China’s acts, policies, and practices covered in the original Section 301 investigation. Among other efforts, ST&R is working with members of Congress to secure a reinstatement of expired exclusions and a renewal of the process for granting new exclusions.